simeprevir

This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

Latest news

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
J&J's share buyback 'doesn't prevent acquisitions'

disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products.
J&J starts to feel biosimilar competition bite

toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
J&J signs $1bn deal with Achillion for hepatitis C therapies

J&J already has one new-generation oral HCV therapy on the market, its NS3/4A protease inhibitor Olysio (simeprevir), but could do with additional drugs in its portfolio in order
Harvoni sales rocket in first quarter

simeprevir), while Merck &Co also has a new treatment in the works.

More from news
Approximately 9 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Taking a strategic approach

Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Medivir names new CEO

simeprevir). “Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Warehousing of HCV patients reaches new high

Gilead’s interferon-free product sofosbuvir and Johnson &Johnson’s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Events Executive: DOE

Account Director – UK Office: Excellent salary and benefits

Account Manager – Healthcare advertising: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Client Services Director- Flexible Working: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Detecting Alzheimer’s ahead of a cure: A focus on promising new research...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?: Or has the digital world has replaced our brain...